MedPath

ENHANCED Device Programming to Reduce Therapies and Improve Quality of Life in Implantable Cardioverter Defibrillator (ICD) Patients

Not Applicable
Conditions
Cardiac Arrhythmias
Registration Number
NCT01715116
Lead Sponsor
M. Meine
Brief Summary

The purpose of this study is to determine whether Enhanced device programming to reduce therapies (i.e. anti tachycardia pacing (ATP) episodes and shocks (both appropriate and inappropriate)) is safe for patients implanted with an Implantable Cardioverter-Defibrillator (ICD). The secondary objective is to examine the impact of Enhanced programming on (i) ATPs and shocks (both appropriate and inappropriate) and (ii) quality of life and distress.

Detailed Description

ICD therapy has become the first-line treatment for the prevention of sudden cardiac death both as primary and secondary prevention due to its proven survival benefits as compared to anti-arrhythmic drugs. However, ICD therapy is associated with a number of complications and shocks that may impair patient quality of life and well being but also influence mortality. Hence, reduction of ICD shocks by means of alternative programming of the device is paramount for improving patient-centered outcomes and mortality.

The ENHANCED-ICD study will be a prospective, single-arm safety monitoring study. All patients will receive Enhanced programming. Furthermore, patients will be asked to complete a set of standardized and validated self-report questionnaires prior to ICD implantation, at 3-, 6-, and 12 months post implantation.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • a primary or secondary prophylactic indication for ICD therapy according to the current European guidelines
  • implanted with a Medtronic ProtectaTM ICD/CRT-D device or any future CE-approved and market-released Medtronic ICD/CRT-D devices with SmartShock technology
  • between 18-80 years of age
  • speaking and understanding Dutch
  • providing written informed consent
Exclusion Criteria
  • a life expectancy less than 1 year
  • a history of psychiatric illness other than affective/anxiety disorders
  • on the waiting list for heart transplantation
  • insufficient knowledge of the Dutch language

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Number of intervention-related safety eventsup to 12 months

Combined safety endpoint: arrhythmic syncope/hospitalization/death/other serious adverse event.

Secondary Outcome Measures
NameTimeMethod
Quality of life12 months post implantation

EuroQol 5D (EQ-5D) and Short Form Health Survey 12 (SF-12)

Distress12 months post implantation

Hospital Anxiety and Depression Scale (HADS)and Patient Health Questionnaire (PHQ-9)

Number of ATPs/shocks12 months post implantation

ATPs/shocks shall be further classified based on: appropriate/inappropriate; successful/unsuccessful.

Trial Locations

Locations (1)

University Medical Center

🇳🇱

Utrecht, Netherlands

University Medical Center
🇳🇱Utrecht, Netherlands
Mathias Meine, MD, PhD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.